Segall Bryant & Hamill’s PTC Therapeutics PTCT Stock Holding History

Segall Bryant & Hamill’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.2M	Buy	271,735 +76,355	+39%	+$5.51M	0.26%	133
2026 Q1	$13.3M	Buy	195,380 +144,949	+287%	+$10.3M	0.19%	186
2025 Q4	$3.83M	Buy	50,431 +12,969	+35%	+$943K	0.05%	344
2025 Q3	$2.3M	Sell	37,462 -272	-0.7%	-$14.2K	0.03%	413
2025 Q2	$1.84M	Buy	+37,734	New	+$1.79M	0.03%	445

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Segall Bryant & Hamill's PTCT Position: Q2 2026 in Review

Segall Bryant & Hamill increased its PTC Therapeutics (PTCT) stake by 39% in Q2 2026, buying an estimated $5.51M and bringing the position to 271,735 shares worth $22.2M. The position accounts for 0.26% of the portfolio, ranked #133.

Segall Bryant & Hamill first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Segall Bryant & Hamill held 271,735 shares of PTC Therapeutics worth $22.2M as of Q2 2026.
Segall Bryant & Hamill bought 76,355 PTC Therapeutics shares in Q2 2026, an estimated $5.51M.
PTC Therapeutics made up 0.26% of Segall Bryant & Hamill's portfolio in Q2 2026, its #133 holding.
Segall Bryant & Hamill first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.